Department of Diabetes & Endocrinology, University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary, Leicester, UK.
Clin Endocrinol (Oxf). 2018 Sep;89(3):354-359. doi: 10.1111/cen.13791. Epub 2018 Jul 11.
To assess the clinical outcome of a strategy of conservative monitoring of patients with nonfunctioning pituitary adenomas (NFPA) after pituitary surgery and in patients without surgery.
Retrospective study of outcomes, using a clinical information system.
An unselected, clinical series of patients seen in a single centre between 1989 and 2015.
Review of clinical information system data to obtain details and dates of surgery, radiotherapy, pituitary imaging and outcomes.
We identified 190 cases of NFPA. Trans-sphenoidal surgery (TSS) had been performed as primary therapy in 132 cases (all macro-adenomas). At a mean 7.6-years follow-up after TSS without immediate pituitary radiotherapy, recurrence occurred in 10.7% of cases with no visible postoperative residual adenoma, 38.8% with intrasellar and 66.7% with extrasellar residuum. Recurrence was defined as growth of residual tumour requiring intervention. On survival analysis, at 10 years, recurrence-free survival was 75% in patients with no residual tumour and 40% with intrasellar residuum. Recurrence occurred in 12.5% of 24 patients who had received postop radiotherapy. Patients were monitored conservatively without initial surgery in 65 patients. After a mean of 5-year monitoring, only 20% required intervention during follow-up (18.5% TSS) and 30.8% died of nonpituitary causes during follow-up.
This study suggests that a conservative approach may be safe and appropriate in patients with NFPA if followed up with appropriate imaging surveillance, whether postoperative or without primary surgery.
评估经蝶窦手术和未经手术的无功能垂体腺瘤(NFPA)患者保守监测策略的临床结果。
使用临床信息系统进行回顾性结局研究。
1989 年至 2015 年间在单一中心就诊的未经选择的临床系列患者。
审查临床信息系统数据以获取手术、放疗、垂体成像和结果的详细信息和日期。
我们确定了 190 例 NFPA 病例。132 例(均为大腺瘤)作为主要治疗方法进行了经蝶窦手术(TSS)。在 TSS 后不立即进行垂体放疗的平均 7.6 年随访中,无可见术后残留腺瘤的病例中有 10.7%复发,鞍内残留的病例中有 38.8%,鞍外残留的病例中有 66.7%。复发定义为需要干预的残留肿瘤生长。在生存分析中,在 10 年内,无残留肿瘤的患者和有鞍内残留肿瘤的患者无复发生存率分别为 75%和 40%。接受术后放疗的 24 例患者中有 12.5%复发。65 例患者未经初始手术接受保守监测。在平均 5 年的监测后,仅 20%在随访期间需要干预(18.5% TSS),30.8%在随访期间死于非垂体原因。
本研究表明,如果对 NFPA 患者进行适当的影像学监测,无论是术后还是未经初次手术,保守方法可能是安全且合适的。